Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease

International Journal of Tuberculosis and Lung Disease

Volumn 21, Issue 9, 2017, Pages 996-1001

  Yoon, H Y ^a   Jo, K W ^a   Nam, G B ^a   Shim, T S ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Cardiovascular events; Combination therapy; MDR TB; NTM; QT prolongation

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIMYCOBACTERIAL AGENT; AZITHROMYCIN; BEDAQUILINE; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DELAMANID; KANAMYCIN; MOXIFLOXACIN; PROTIONAMIDE; MACROLIDE; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; ATRIAL FIBRILLATION; ATYPICAL MYCOBACTERIOSIS; CAUSE OF DEATH; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; DRUG WITHDRAWAL; FEMALE; HEART ARREST; HEART TAMPONADE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PERICARDITIS; PRIORITY JOURNAL; QT PROLONGATION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; AGED; ATYPICAL MYCOBACTERIUM; CHILD; FOLLOW UP; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; AZITHROMYCIN; CHILD; CLARITHROMYCIN; CLOFAZIMINE; DIARYLQUINOLINES; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HUMANS; LOST TO FOLLOW-UP; MACROLIDES; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; NONTUBERCULOUS MYCOBACTERIA; OXAZOLES; RETROSPECTIVE STUDIES; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 85028072675     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.17.0174     Document Type: Article

References (30)

1. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. WHO/HTM/TB/ 2016.04. Geneva, Switzerland: WHO, 2016.
2. Floto R A, Olivier K N, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016; 71: i1-i22.
3. endTB Project. Clinical and programmatic guide for patient management with new TB drugs. Version 3.3. Boston, MA, USA: Partners in Health, 2016. http://endtb.org/resources/ endtb-clinical-guide-v33 Accessed June 2107.
4. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drugresistant tuberculosis. WHO/HTM/TB/2014.11. Geneva, Switzerland: WHO, 2014.
5. Shah R R. The significance of QT interval in drug development. Br J Clin Pharmacol 2002; 54: 188-202.
6. Roden D M. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-1022.
7. Al-Khatib S M, LaPointe N M, Kramer J M, Califf R M. What clinicians should know about the QT interval. JAMA 2003; 289: 2120-2127.
8. Trinkley K E, Page R L, 2nd, Lien H, Yamanouye K, Tisdale J E. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin 2013; 29: 1719-1726.
9. Altmann D, Eggmann U, Ammann P. Drug induced QT prolongation. Wien Klin Wochenschr 2008; 120: 128-135.
10. Drew B J, Ackerman M J, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010; 121: 1047-1060.
11. Roden D M. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-1022.
12. Harausz E, Cox H, Rich M, Mitnick C D, Zimetbaum P, Furin J. QTc prolongation and treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2015; 19: 385-391.
13. Wallis R S. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur Respir J 2016; 48: 1526-1527.
14. Briasoulis A, Agarwal V, Pierce W J. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology 2011; 120: 103-110.
15. Griffith D E, Aksamit T, Brown-Elliott B A, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
16. Fox G J, Menzies D. A review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis. Infect Dis Ther 2013; 2: 123-144.
17. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
18. Indik J H, Pearson E C, Fried K, Woosley R L. Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QTinterval. Heart Rhythm 2006; 3: 1003-1007.
19. Luo S, Michler K, Johnston P, Macfarlane PW. A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. J Electrocardiol 2004; 37 (Suppl): 81-90.
20. Charbit B, Samain E, Merckx P, Funck-Brentano C. QTinterval measurement: evaluation of automatic QTc measurement and new simple method to calculate and interpret corrected QT interval. Anesthesiology 2006; 104: 255-260.
21. Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol 1993; 72: 17b-22b.
22. Choudhri S H, Harris L, Butany JW, Keystone J S. Clofazimine induced cardiotoxicity - a case report. Lepr Rev 1995; 66: 63-68.
23. Owens R C, Jr, Ambrose P G. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41 (Suppl 2): S144-S157.
24. Stahlmann R, Lode HM. Risks associated with the therapeutic use of fluoroquinolones. Expert Opin Drug Saf 2013; 12: 497-505.
25. Abu-Gharbieh E, Vasina V, Poluzzi E, De Ponti F. Antibacterial macrolides: a drug class with a complex pharmacological profile. Pharmacol Res 2004; 50: 211-222.
26. Koide T, Shiba M, Tanaka K, et al. Severe QT interval prolongation associated with moxifloxacin: a case report. Cases Journal 2008; 1: 409-409.
27. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drugresistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014; 44: 811-815.
28. Tadolini M, Lingtsang R D, Tiberi S, et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Eur Respir J 2016; 48: 935-938
29. Guglielmetti L, Jaspard M, Le Du D, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrugresistant tuberculosis. Eur Respir J 2017; 49: 1 601 799.
30. Zhang Y, PostWS, Blasco-Colmenares E, Dalal D, Tomaselli G F, Guallar E. Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology 2011; 22: 660-670.